Market Research Firm Polaris Leverages 70+ Sources to Serve 1,000+ Global Clients

In an era where data is abundant but actionable insight remains scarce, organizations across industries are moving beyond generic market reports. The shift demands not just volume of data, but verified, cross-referenced intelligence that can directly inform strategic planning—whether for entering a new geography, launching a therapy, or allocating R&D budgets. Polaris Market Research, a market research firm headquartered in New York, has positioned itself at the center of this transformation. With a client roster exceeding 1,000 organizations and a library of more than 5,000 reports spanning 15+ sectors, the company offers both syndicated reports for rapid benchmarking and custom studies tailored to niche requirements. This article examines Polaris's methodology, real-world client outcomes, and four emerging market reports to understand how tailored intelligence is reshaping decision-making in high-growth niches.

[IMAGE: Infographic showing the 15+ industry sectors covered with icons, connected to a central Polaris logo.]

The Data Intelligence Engine: Methodology and Credibility

At the core of Polaris Market Research’s offering is a rigorous cross-referencing process that draws from over 70 authoritative sources—government databases, patent filings, trade journals, academic publications, and primary interviews with industry executives. Rather than relying on a single data stream, analysts triangulate information to identify discrepancies and validate trends. This approach is particularly critical in industries like healthcare and chemicals, where regulatory shifts and patent expirations can alter market dynamics within months.

The company operates on a dual-track model. Syndicated reports—such as those covering radiopharmaceuticals or peptide therapeutics—are published on a synchronized release cycle. For example, reports issued in June 2026 include forecasts extending to 2034, giving clients a forward-looking lens that aligns with annual strategic planning cycles. For clients that require deeper granularity—say, a competitive landscape for a specific compound in a specific country—Polaris offers customized studies that blend its existing database with proprietary primary research.

[IMAGE: Flowchart illustrating data collection from 70+ sources → cross-referencing → report generation with forecast arrows.]

This methodology has earned the firm credibility among Fortune 500 companies and specialized research institutes alike. The ability to deliver a comprehensive view across industries—from automotive electrification to non-Hodgkin lymphoma therapeutics—is underpinned by a team of analysts with domain-specific expertise. As one client described, the difference lies not in having data, but in having data that has been scrubbed, weighted, and contextualized for a specific business decision.

Client Success Stories: From Finance to Rail – The Universal Need for Deep Insights

Polaris’s client base spans sectors as diverse as financial services, chemicals, food science, and rail transportation. Four testimonials—from Mastercard, Mitsubishi Chemical Corporation, the World Institute of Kimchi, and the Korea Railroad Research Institute—illustrate the breadth of needs that customized market intelligence can address.

Mastercard: The global payments network sought to identify emerging regional markets and segments that might fit its business model expansion. Polaris delivered a custom analysis that mapped untapped payment corridors, consumption patterns, and regulatory environments. The result was a data-backed portfolio of target markets, enabling Mastercard to prioritize investments with higher confidence.

Mitsubishi Chemical Corporation: For a strategic planning exercise, Mitsubishi required a competitive analysis of specialty chemicals in the Asia-Pacific region. Polaris’s team created a custom report that benchmarked competitors on R&D spend, patent filings, and capacity expansions. The client noted that the report’s granularity—down to plant-level output estimates—helped inform a multi-year investment roadmap.

World Institute of Kimchi: This South Korean research institute needed global consumption and export trend data for kimchi and fermented foods to support industry promotion initiatives. Polaris drew from trade statistics, consumer surveys, and retail channel data to produce a syndicated report that has since been cited in government export strategy documents.

Korea Railroad Research Institute (KRRI): KRRI required future forecasts on railway electrification and battery technologies to guide its R&D portfolio. Polaris’s report on rail infrastructure trends, combined with a custom module on lithium-ion battery adoption in rolling stock, provided the institute with scenario-based projections that directly influenced its next project cycle.

Across these cases, common themes emerge: responsiveness to specific queries, willingness to customize beyond standard templates, data-backed forecasts with transparent assumptions, and professional project management. Clients consistently highlight that the intelligence they received was not a generic commodity but a decision-making tool shaped around their business model.

[IMAGE: Collage of logos (Mastercard, Mitsubishi, Kimchi Institute, KRRI) with a central quote bubble saying 'Data-backed insights that fit our business model.']

Spotlight on Four High-Growth Markets: What the Reports Reveal

To understand the type of industry trends Polaris captures, four recently published reports offer a window into emerging patterns in healthcare, veterinary medicine, and oncology.

Radiopharmaceuticals (Report PM6029)

The radiopharmaceuticals market is being reshaped by the convergence of theranostics—the combination of diagnostic imaging and targeted therapy—and personalized medicine. Polaris’s report, covering 2026–2034, identifies regulatory tailwinds from agencies like the U.S. FDA and EMA that are accelerating approvals for novel radioligand therapies. Key growth drivers include increasing adoption of alpha-emitting isotopes and expanding indications beyond prostate cancer and neuroendocrine tumors. The report cross-references clinical trial databases, reimbursement policies, and supply chain constraints for medical isotopes, offering a holistic view for pharmaceutical companies and contract development organizations.

Peptide Therapeutics (PM6027)

Peptide-based drugs are experiencing a renaissance, driven by advances in targeted protein degradation and metabolic disease applications. Polaris’s analysis highlights a cross-sector demand—from oncology to cardiovascular disease to antimicrobial resistance. The report notes that the number of peptide drugs entering clinical trials has grown over 30% year-over-year since 2022, with manufacturing innovations such as solid-phase peptide synthesis enabling cost-effective scale-up. For biotechnology firms and large pharma, the forecast provides a map of competitive intensity by therapeutic area and region.

U.S. Animal Wound Care (PM6012)

The pet humanization trend—where owners spend increasingly on advanced veterinary care—is fueling a niche but rapidly expanding market. Polaris’s U.S. animal wound care report examines the shift from traditional bandages to advanced wound dressings incorporating hydrogels, antimicrobial agents, and growth factors. The report segments demand by animal type (canine, feline, equine) and wound type (surgical, traumatic, chronic). For veterinary product manufacturers, the data on distribution channel dynamics and pricing trends provides a basis for go-to-market strategies in a market projected to grow at a double-digit CAGR through 2034.

Non-Hodgkin Lymphoma Therapeutics (PM6035)

With the global non-Hodgkin lymphoma (NHL) therapeutics market driven by aging populations and rising incidence rates, Polaris’s report focuses on the evolving treatment paradigm: from chemotherapy to CAR-T cell therapies, bispecific antibodies, and targeted small molecules. The analysis includes a pipeline assessment of over 40 investigational agents and a competitive landscape featuring Bristol Myers Squibb, Roche, and Novartis. A key insight is the increasing role of biomarker-driven patient stratification, which is expected to reshape clinical trial designs and reimbursement criteria. The report serves as a strategic tool for biopharma executives evaluating portfolio gaps and licensing opportunities.

[IMAGE: Four report covers or graphical abstracts representing radiopharmaceuticals, peptide therapeutics, animal wound care, and NHL therapeutics, side by side.]

Conclusion: Why Custom Intelligence Matters in a Crowded Field

The market research industry is crowded, with hundreds of firms offering overlapping data sets. Polaris Market Research differentiates itself not by claiming to have more data, but by demonstrating how its cross-referencing methodology and willingness to customize produce insights that clients actually use. The testimonials from Mastercard, Mitsubishi Chemical Corporation, the World Institute of Kimchi, and the Korea Railroad Research Institute underscore a universal truth: in strategic planning, the gap between a generic trend and a business-specific forecast can determine whether a multi-million-dollar decision succeeds or fails.

As industries from healthcare to transportation continue to evolve at an accelerating pace, the demand for forward-looking, customized market intelligence will only grow. Polaris’s synchronized release cycle—with reports published in June 2026 and forecasts extending to 2034—reflects an understanding that decision-makers need both a current snapshot and a long-range compass. For organizations navigating high-growth niches such as radiopharmaceuticals, peptide therapeutics, animal wound care, and non-Hodgkin lymphoma therapeutics, the ability to access data that has been verified, contextualized, and tailored is no longer a luxury—it is a competitive necessity.

[IMAGE: A clean, professional infographic showing a timeline from 2026 to 2034 with milestones for each of the four featured markets, overlaid with icons representing healthcare, chemicals, and technology.]